Literature DB >> 24899227

Enhanced factor VIIIa stability of A2 domain interface variants results from an increased apparent affinity for the A2 subunit. Results from an increased apparent affinity for the A2 subunit.

M Monaghan1, H Wakabayashi2, A Griffiths, J Wintermute, P J Fay.   

Abstract

Factor (F)VIIIa, a heterotrimer comprised of A1, A2, and A3C1C2 subunits, is labile due to the tendency of the A2 subunit to dissociate from the A1/A3C1C2 dimer. As dissociation of the A2 subunit inactivates FVIIIa activity, retention of A2 defines FVIIIa stability and thus, FXase activity. Earlier results showed that replacing residues D519, E665, and E1984 at the A2 domain interface with Ala or Val reduced rates of FVIIIa decay, increasing FXa and thrombin generation. We now show the enhanced FVIIIa stability of these variants results from increases in inter-A2 subunit affinity. Using a FVIIIa reconstitution assay to monitor inter-subunit affinity by activity regeneration, the apparent Kd value for the interaction of wild-type (WT) A2 subunit with WT A1/A3C1C2 dimer (43 ± 2 nM) was significantly higher than values observed for the A2 point mutants D519A/V, E665A/V, and E1984A/V which ranged from ~5 to ~19 nM. Val was determined to be the optimal hydrophobic residue at position 665 (apparent Kd = 5.1 ± 0.7 nM) as substitutions with Ile or Leu at this position increased the apparent Kd value by ~3- and ~7-fold, respectively. Furthermore, the double mutant (D519V/E665V) showed an ~47-fold lower apparent Kd value (0.9 ± 0.6 nM) than WT. Thus these hydrophobic mutations at the A2 subunit interfaces result in high binding affinities for the A2 subunit and correlate well with previously observed reductions in rates in FVIIIa decay.

Entities:  

Keywords:  Factor VIII; factor VIIIa; inter-subunit binding affinity; protein stability

Mesh:

Substances:

Year:  2014        PMID: 24899227      PMCID: PMC4469990          DOI: 10.1160/TH14-01-0086

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  25 in total

Review 1.  Activation of factor VIII and mechanisms of cofactor action.

Authors:  Philip J Fay
Journal:  Blood Rev       Date:  2004-03       Impact factor: 8.250

2.  Residues 110-126 in the A1 domain of factor VIII contain a Ca2+ binding site required for cofactor activity.

Authors:  Hironao Wakabayashi; Jan Freas; Qian Zhou; Philip J Fay
Journal:  J Biol Chem       Date:  2004-01-13       Impact factor: 5.157

3.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

4.  Hemophilia A mutations associated with 1-stage/2-stage activity discrepancy disrupt protein-protein interactions within the triplicated A domains of thrombin-activated factor VIIIa.

Authors:  S W Pipe; E L Saenko; A N Eickhorst; G Kemball-Cook; R J Kaufman
Journal:  Blood       Date:  2001-02-01       Impact factor: 22.113

5.  Increasing hydrophobicity or disulfide bridging at the factor VIII A1 and C2 domain interface enhances procofactor stability.

Authors:  Hironao Wakabayashi; Amy E Griffiths; Philip J Fay
Journal:  J Biol Chem       Date:  2011-05-31       Impact factor: 5.157

6.  Hemophilia A mutations within the factor VIII A2-A3 subunit interface destabilize factor VIIIa and cause one-stage/two-stage activity discrepancy.

Authors:  William H Hakeos; Hongzhi Miao; Nongnuch Sirachainan; Geoffrey Kemball-Cook; Evgueni L Saenko; Randal J Kaufman; Steven W Pipe
Journal:  Thromb Haemost       Date:  2002-11       Impact factor: 5.249

7.  pH-dependent denaturation of thrombin-activated porcine factor VIII.

Authors:  P Lollar; C G Parker
Journal:  J Biol Chem       Date:  1990-01-25       Impact factor: 5.157

8.  An engineered interdomain disulfide bond stabilizes human blood coagulation factor VIIIa.

Authors:  A J Gale; J-L Pellequer
Journal:  J Thromb Haemost       Date:  2003-09       Impact factor: 5.824

9.  Expression and characterization of recombinant murine factor VIII.

Authors:  Christopher Doering; Ernest T Parker; John F Healey; Heather N Craddock; Rachel T Barrow; Pete Lollar
Journal:  Thromb Haemost       Date:  2002-09       Impact factor: 5.249

10.  Phospholipid vesicle formation and transmembrane protein incorporation using octyl glucoside.

Authors:  L T Mimms; G Zampighi; Y Nozaki; C Tanford; J A Reynolds
Journal:  Biochemistry       Date:  1981-02-17       Impact factor: 3.162

View more
  3 in total

1.  Stabilizing interactions between D666-S1787 and T657-Y1792 at the A2-A3 interface support factor VIIIa stability in the blood clotting pathway.

Authors:  M Monaghan; H Wakabayashi; A E Griffiths; P J Fay
Journal:  J Thromb Haemost       Date:  2016-03-21       Impact factor: 5.824

2.  The 3.2 Å structure of a bioengineered variant of blood coagulation factor VIII indicates two conformations of the C2 domain.

Authors:  Ian W Smith; Anne E d'Aquino; Christopher W Coyle; Andrew Fedanov; Ernest T Parker; Gabriela Denning; Harold Trent Spencer; Pete Lollar; Christopher B Doering; Paul Clint Spiegel
Journal:  J Thromb Haemost       Date:  2019-09-08       Impact factor: 5.824

3.  Correction of bleeding in experimental severe hemophilia A by systemic delivery of factor VIII-encoding mRNA.

Authors:  Jules Russick; Sandrine Delignat; Peter Milanov; Olivier Christophe; Gábor Boros; Cécile V Denis; Peter J Lenting; Srinivas V Kaveri; Sébastien Lacroix-Desmazes
Journal:  Haematologica       Date:  2019-07-09       Impact factor: 9.941

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.